欧康维视生物老花眼新药获批III期临床

健识局
19 Jun

近日,欧康维视宣布治疗成人老视新药OT-802(盐酸毛果芸香碱滴眼液)获CDE批准开展III期临床试验。公司计划开展一项评价OT-802滴眼液治疗中国老视患者有效性和安全性的随机、双盲、安慰剂对照、平行组、多中心III期临床。老花眼是随着年龄的增长而出现的常见视力衰退,影响全球近20亿人。老花眼通常在40岁之后出现,目前大多数治疗方法是佩戴老花镜,但是对很多人来说并不方便。国内目前尚无已经商业化的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10